^
Association details:
| Biomarker: | REV1 2108G > A |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Identification and prognostic analysis of the cetuximab resistance-related gene REV1 in RAS wild-type metastatic colorectal cancer
Published date:
06/15/2021
Excerpt:
Then, PFS analysis of the 70 patients was used to verify the correlation between the candidate gene and cetuximab sensitivity….Survival analysis suggested REV1: c.2108G > A was associated with rapid disease progression (median PFS time, REV1 mutant vs. REV1 wild-type: 4.4 months vs. 8.7 months, P = 0.034).
